[go: up one dir, main page]

HK1231490A1 - Modified antigen binding polypeptide constructs and uses thereof - Google Patents

Modified antigen binding polypeptide constructs and uses thereof Download PDF

Info

Publication number
HK1231490A1
HK1231490A1 HK17105010.6A HK17105010A HK1231490A1 HK 1231490 A1 HK1231490 A1 HK 1231490A1 HK 17105010 A HK17105010 A HK 17105010A HK 1231490 A1 HK1231490 A1 HK 1231490A1
Authority
HK
Hong Kong
Prior art keywords
sub
heterodimer
heavy chain
amino acid
chain
Prior art date
Application number
HK17105010.6A
Other languages
Chinese (zh)
Inventor
Mario SANCHES
Thomas SPRETER VON KREUDENSTEIN
Dunja UROSEV
Igor Edmondo Paolo D'angelo
Stacey A. L. Tom-Yew
Surjit Bhimarao Dixit
Adam Louis CORPER
Yang-Chieh CHOU
Original Assignee
Zymeworks, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymeworks, Inc. filed Critical Zymeworks, Inc.
Publication of HK1231490A1 publication Critical patent/HK1231490A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof. At least one of the heterodimers can comprise one or more amino acid modifications in the C<sub>Hl</sub> and/or C<sub>L</sub> domains, one or more amino acid modifications in the V<sub>H</sub> and/or V<sub>L</sub> domains, or a combination thereof. The modified amino acid(s) can be part of the interface between the light chain and heavy chain and are typically modified to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer typically preferentially pairs with the second light chain rather than first.
HK17105010.6A 2014-05-28 2015-05-29 Modified antigen binding polypeptide constructs and uses thereof HK1231490A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462003663P 2014-05-28 2014-05-28
US62/003,663 2014-05-28
US201562154055P 2015-04-28 2015-04-28
US62/154,055 2015-04-28
PCT/IB2015/054107 WO2015181805A1 (en) 2014-05-28 2015-05-29 Modified antigen binding polypeptide constructs and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
HK42022066308.2A Division HK40077442A (en) 2014-05-28 2017-05-18 Modified antigen binding polypeptide constructs and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
HK42022066308.2A Addition HK40077442A (en) 2014-05-28 2017-05-18 Modified antigen binding polypeptide constructs and uses thereof

Publications (1)

Publication Number Publication Date
HK1231490A1 true HK1231490A1 (en) 2017-12-22

Family

ID=54698217

Family Applications (1)

Application Number Title Priority Date Filing Date
HK17105010.6A HK1231490A1 (en) 2014-05-28 2015-05-29 Modified antigen binding polypeptide constructs and uses thereof

Country Status (12)

Country Link
US (3) US11306156B2 (en)
EP (2) EP3107938B1 (en)
KR (1) KR102493430B1 (en)
AU (3) AU2015265457B2 (en)
BR (1) BR112016027888A2 (en)
CA (3) CA3244731A1 (en)
DK (1) DK3107938T3 (en)
EA (1) EA201692476A1 (en)
HK (1) HK1231490A1 (en)
MX (2) MX392772B (en)
RU (1) RU2729467C2 (en)
WO (1) WO2015181805A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12060436B2 (en) 2012-11-28 2024-08-13 Zymeworks Bc Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
PH12013500974A1 (en) 2010-11-17 2013-07-08 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
AU2012332021B8 (en) 2011-11-04 2017-10-12 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
US9499634B2 (en) 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
EP2904093B1 (en) 2012-10-03 2019-04-10 Zymeworks Inc. Methods of quantitating heavy and light chain polypeptide pairs
MX385344B (en) 2012-11-28 2025-03-18 Zymeworks Bc Inc GENETICALLY MODIFIED IMMUNOGLOBULIN HEAVY CHAIN-LIGHT CHAIN PAIRS AND THEIR USES.
HK1231490A1 (en) * 2014-05-28 2017-12-22 Zymeworks, Inc. Modified antigen binding polypeptide constructs and uses thereof
CA2963692A1 (en) * 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
JP6952605B2 (en) 2015-04-24 2021-10-20 ジェネンテック， インコーポレイテッド Multispecific antigen binding protein
KR102669686B1 (en) * 2015-04-28 2024-05-29 자임워크스 비씨 인코포레이티드 Modified antigen binding polypeptide constructs and uses thereof
TWI744242B (en) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Antibody constructs for egfrviii and cd3
TWI829617B (en) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Antibody constructs for flt3 and cd3
TWI796283B (en) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Antibody constructs for msln and cd3
EA039859B1 (en) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Bispecific antibody constructs binding egfrviii and cd3
EP4524161A3 (en) * 2015-10-08 2025-06-04 Zymeworks BC Inc. Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
US20200270363A1 (en) 2015-12-25 2020-08-27 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
EP3397646A1 (en) * 2015-12-28 2018-11-07 Massachusetts Institute of Technology Bispecific antibodies having constant region mutations and uses therefor
MA43959A (en) 2016-02-03 2018-12-12 Amgen Res Munich Gmbh CONSTRUCTIONS OF ANTIBODIES INVOLVING BISPECIFIC PSMA AND CD3 T-CELLS
WO2017165464A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
UA126900C2 (en) 2016-04-28 2023-02-22 Чугаі Сейяку Кабусікі Кайся ANTIBODY CONTAINING DRUG
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
EP3455243B1 (en) 2016-05-11 2021-03-24 Cytiva BioProcess R&D AB Separation matrix
JP7031934B2 (en) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ Separation matrix
US11708390B2 (en) 2016-05-11 2023-07-25 Cytiva Bioprocess R&D Ab Method of storing a separation matrix
US11753438B2 (en) 2016-05-11 2023-09-12 Cytiva Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
US11820828B2 (en) * 2016-12-22 2023-11-21 Eli Lilly And Company Methods for producing fabs and IgG bispecific antibodies
US20200291089A1 (en) 2017-02-16 2020-09-17 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
JOP20190222A1 (en) 2017-04-11 2019-09-24 Zymeworks Inc Anti-pd-l1-anti-tim-3 bispecific antibodies
US20210246227A1 (en) 2017-05-31 2021-08-12 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
KR102611853B1 (en) 2017-06-30 2023-12-08 자임워크스 비씨 인코포레이티드 Stabilized chimeric FABS
AR112603A1 (en) 2017-07-10 2019-11-20 Lilly Co Eli BIS SPECIFIC ANTIBODIES CONTROL POINT INHIBITORS
IL273592B2 (en) 2017-09-29 2025-11-01 Chugai Pharmaceutical Co Ltd A multispecific antigen-binding molecule with activity that replaces the function of a cofactor for blood coagulation factor VIII (FVIII), and a pharmaceutical formulation containing the molecule as an active ingredient
JPWO2019088143A1 (en) 2017-11-01 2020-11-12 中外製薬株式会社 Antibody variants and isoforms with reduced bioactivity
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN-BINDING CONSTRUCTS AND GENERALLY MODIFIED T-CELLS FOR THE TREATMENT OF DISEASES
KR102471868B1 (en) * 2018-01-15 2022-11-30 아이-맵 바이오파마 유에스 리미티드 Modified CK and CH1 domains
WO2019148410A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2019178364A2 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
WO2019178539A1 (en) * 2018-03-16 2019-09-19 Ngm Biopharmaceuticals, Inc. Bispecific antibodies
US11408840B2 (en) 2018-06-28 2022-08-09 Just-Evotec Biologics, Inc. High throughput interrogation of physiochemical properties of a protein
CN112955465A (en) 2018-07-03 2021-06-11 马伦戈治疗公司 anti-TCR antibody molecules and uses thereof
WO2020127376A2 (en) * 2018-12-17 2020-06-25 Alligator Bioscience Ab Novel polypeptides
GB201820556D0 (en) * 2018-12-17 2019-01-30 Alligator Bioscience Ab Novel polypeptides
EP3674316A1 (en) * 2018-12-24 2020-07-01 Sanofi Multispecific binding proteins with mutant fab domains
JP2022515424A (en) * 2018-12-24 2022-02-18 サノフイ Multispecific binding protein with mutated fab domain
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
CA3130628A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
CN114127113A (en) 2019-02-21 2022-03-01 马伦戈治疗公司 Multifunctional molecules binding to calreticulin and uses thereof
CN114026122B (en) 2019-02-21 2024-12-31 马伦戈治疗公司 Multifunctional molecules that bind to T cell-associated cancer cells and their uses
CA3131014A1 (en) 2019-02-21 2020-08-27 Andreas Loew Anti-tcr antibody molecules and uses thereof
EP4084821A4 (en) 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. CD33-BINDING MULTIFUNCTIONAL MOLECULES AND THEIR USES
EP4084823A4 (en) 2020-01-03 2024-05-15 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
KR20230028242A (en) 2020-04-24 2023-02-28 마렝고 테라퓨틱스, 인크. Multifunctional molecules that bind to T cell-associated cancer cells and their uses
BR112022025019A2 (en) * 2020-06-17 2022-12-27 Medimmune Ltd RELAXIN HETERODIMERIC FUSIONS AND USES THEREOF
CA3190766A1 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
CN116249718A (en) 2020-08-26 2023-06-09 马伦戈治疗公司 Multifunctional molecules binding to calreticulin and uses thereof
WO2022047046A1 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Methods of detecting trbc1 or trbc2
WO2022216993A2 (en) 2021-04-08 2022-10-13 Marengo Therapeutics, Inc. Multifuntional molecules binding to tcr and uses thereof
JP2024530402A (en) * 2021-07-12 2024-08-21 ジェネンテック， インコーポレイテッド Structures for reducing antibody-lipase binding
CN118265726A (en) * 2021-08-25 2024-06-28 广州凌腾生物医药有限公司 Heterodimer immunoglobulin
CN114106192B (en) * 2021-12-20 2024-06-14 广州爱思迈生物医药科技有限公司 Bispecific antibodies and uses thereof
AR129445A1 (en) 2022-05-27 2024-08-28 Glaxosmithkline Ip Dev Ltd USE OF TNF-a BINDING PROTEINS AND IL-7 BINDING PROTEINS IN MEDICAL TREATMENT
CN121177510A (en) 2022-11-24 2025-12-23 广州百济神州生物制药有限公司 Anti-CEA antibody drug conjugates and usage methods
CN120603850A (en) 2023-01-19 2025-09-05 广州百济神州生物制药有限公司 Anti-CMET antibodies and methods of use
TW202436343A (en) 2023-03-03 2024-09-16 瑞士商百濟神州瑞士有限責任公司 Muc1 and cd16a antibodies and methods of use
AR132041A1 (en) 2023-03-03 2025-05-21 Beigene Switzerland Gmbh CD16A ANTIBODIES AND METHODS OF USE
KR20250159040A (en) * 2023-03-03 2025-11-07 아스트라제네카 아베 Pharmaceutical formulations comprising heterodimeric relaxin fusion proteins and uses thereof
AR132043A1 (en) 2023-03-03 2025-05-21 Beigene Switzerland Gmbh MUC1 ANTIBODIES AND METHODS OF USE
TW202436353A (en) 2023-03-06 2024-09-16 瑞士商百濟神州瑞士有限責任公司 Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
AR132064A1 (en) 2023-03-06 2025-05-21 Beigene Switzerland Gmbh ANTI-CLDN6 ANTIBODIES AND METHODS OF USE
TW202436345A (en) 2023-03-06 2024-09-16 瑞士商百濟神州瑞士有限責任公司 Anti-cd3 multispecific antibodies and methods of use
WO2025125137A1 (en) 2023-12-11 2025-06-19 Glaxosmithkline Intellectual Property Development Limited Baff specific antibodies
WO2025262216A1 (en) 2024-06-21 2025-12-26 Glaxosmithkline Intellectual Property Development Limited Multispecific antigen binding proteins binding to il23 and il18
WO2026011013A1 (en) 2024-07-02 2026-01-08 Epibiologics, Inc. Binding agents and uses thereof
WO2026021476A1 (en) 2024-07-24 2026-01-29 Beone Guangzhou Biologics Manufacturing Co., Ltd. Anti-cmet and anti-egfr multispecific antibody drug conjugates

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI85768C (en) 1990-07-04 1992-05-25 Valtion Teknillinen Method for performing surface plasmon resonance measurement and in method t useful sensor
EP0517930B1 (en) 1991-06-08 1995-05-24 Hewlett-Packard GmbH Method and apparatus for detecting the presence and/or concentration of biomolecules
JPH08500017A (en) 1992-08-17 1996-01-09 ジェネンテク，インコーポレイテッド Bispecific immune adhesin
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
EP0904278A4 (en) 1996-03-22 1999-09-15 Human Genome Sciences Inc Apoptosis inducing molecule ii
GB9623820D0 (en) 1996-11-16 1997-01-08 Secr Defence Surface plasma resonance sensor
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
WO1999023105A1 (en) 1997-11-03 1999-05-14 Human Genome Sciences, Inc. Vegi, an inhibitor of angiogenesis and tumor growth
ES2234241T3 (en) 1998-01-23 2005-06-16 Vlaams Interuniversitair Instituut Voor Biotechnologie DERIVATIVES OF ANTIBODY OF MULTIPLE PURPOSES.
CA2319429A1 (en) 1998-05-20 1999-11-25 Graffinity Pharmaceutical Design Gmbh Surface plasmon resonance sensor for the simultaneous measurement of a plurality of samples in fluid form
US6289286B1 (en) 1998-05-29 2001-09-11 Biacore Ab Surface regeneration of biosensors and characterization of biomolecules associated therewith
AU2001245835A1 (en) 2000-03-15 2001-09-24 Heska Corporation Three-dimensional model of a complex between a Fc epsilon receptor alpha chain and a Fc region of an IgE antibody and uses thereof
US20030129659A1 (en) 2001-12-03 2003-07-10 Whelihan E. Fayelle Library screening
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
AU2004242614B2 (en) 2003-05-30 2011-09-22 Merus N.V. Fab library for the preparation of anti vegf and anti rabies virus fabs
US8005620B2 (en) * 2003-08-01 2011-08-23 Dna Twopointo Inc. Systems and methods for biopolymer engineering
US8150634B1 (en) 2004-11-12 2012-04-03 Bristol-Myers Squibb Company Protein-ligand NOE matching for high-throughput structure determination
WO2006106905A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
NZ591252A (en) 2006-03-17 2012-06-29 Biogen Idec Inc Methods of designing antibody or antigen binding fragments thereof with substituted non-covarying amino acids
PT1999154E (en) 2006-03-24 2013-01-24 Merck Patent Gmbh Engineered heterodimeric protein domains
JP5144499B2 (en) 2006-03-31 2013-02-13 中外製薬株式会社 Antibody modification method for purifying bispecific antibodies
WO2007137760A2 (en) 2006-05-25 2007-12-06 Bayer Schering Pharma Aktiengesellschaft Dimeric molecular complexes
US20070274985A1 (en) 2006-05-26 2007-11-29 Stefan Dubel Antibody
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
MX2009010282A (en) 2007-03-29 2009-10-12 Genmab As Bispecific antibodies and methods for production thereof.
WO2008131242A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
WO2009068649A2 (en) 2007-11-30 2009-06-04 Glaxo Group Limited Antigen-binding constructs
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
SI2235064T1 (en) 2008-01-07 2016-04-29 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US20100075326A1 (en) 2008-09-12 2010-03-25 Cornell University Yeast surface two-hybrid system for quantitative detection of protein-protein interactions
CA2738568C (en) 2008-10-01 2024-02-20 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
KR20110104032A (en) 2008-12-19 2011-09-21 마크로제닉스, 인크. Covalently Bonded Diabodies and Their Uses
CA2750533A1 (en) 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
KR101431318B1 (en) 2009-04-02 2014-08-20 로슈 글리카트 아게 Multispecific antibodies comprising full length antibodies and single chain fab fragments
JP5612663B2 (en) 2009-04-07 2014-10-22 ロシュ グリクアート アクチェンゲゼルシャフト Bispecific anti-ErbB-1 / anti-c-Met antibody
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
PE20120540A1 (en) 2009-05-27 2012-05-09 Hoffmann La Roche THREE-SPECIFIC OR TETRA-SPECIFIC ANTIBODIES
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
CA2766220C (en) 2009-06-26 2021-02-09 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2781539C (en) 2009-11-23 2021-07-20 Amgen Inc. Monomeric antibody fc
US10706955B2 (en) 2010-03-23 2020-07-07 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2011120135A1 (en) 2010-03-29 2011-10-06 Zymeworks, Inc. Antibodies with enhanced or suppressed effector function
ES2989108T3 (en) 2010-04-20 2024-11-25 Genmab As Proteins containing heterodimeric antibody FC and methods for producing the same
TW201742925A (en) 2010-04-23 2017-12-16 建南德克公司 Production of heteromultimeric proteins
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CA2800769C (en) 2010-05-27 2021-11-02 Genmab A/S Monoclonal antibodies against her2 epitope
TW201217527A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
WO2012020096A1 (en) 2010-08-13 2012-02-16 Medimmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
CA2808482C (en) 2010-08-16 2021-10-26 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
MX349057B (en) * 2010-11-30 2017-07-07 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT THAT INDUCES CYTOTOXICITY.
CN102153650B (en) 2011-01-27 2012-07-04 中国人民解放军军事医学科学院生物工程研究所 Anti-EGFR (epidemic growth factor receptor) humanized antibody L2-H3 and coding gene and application thereof
EP2688909A2 (en) * 2011-03-25 2014-01-29 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
WO2012143523A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecifc antibodies against her2
RU2641256C2 (en) 2011-06-30 2018-01-16 Чугаи Сейяку Кабусики Кайся Heterodimerizated polypeptide
EP2543680A1 (en) 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
RS56879B1 (en) 2011-08-23 2018-04-30 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
SG10201805291TA (en) 2011-10-27 2018-08-30 Genmab As Production of heterodimeric proteins
ES2732712T3 (en) 2011-10-31 2019-11-25 Chugai Pharmaceutical Co Ltd Antigen binding molecule that has a regulated conjugation between the heavy chain and the light chain
AU2012332021B8 (en) 2011-11-04 2017-10-12 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
DK2794905T3 (en) 2011-12-20 2020-07-06 Medimmune Llc MODIFIED POLYPEPTIDES FOR BISPECIFIC ANTIBODY BASIC STRUCTURES
WO2013152860A2 (en) 2012-04-11 2013-10-17 Dutalys Gmbh Improved antibody light chains
WO2013166594A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
US9499634B2 (en) 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
DE102012105864A1 (en) 2012-07-02 2014-02-20 Continental Reifen Deutschland Gmbh Vehicle tires
CA2878640C (en) 2012-07-13 2023-10-24 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
WO2014012085A2 (en) 2012-07-13 2014-01-16 Zymeworks Inc. Bispecific asymmetric heterodimers comprising anti-cd3 constructs
WO2014018572A2 (en) 2012-07-23 2014-01-30 Zymeworks Inc. Immunoglobulin constructs comprising selective pairing of the light and heavy chains
EP2904093B1 (en) 2012-10-03 2019-04-10 Zymeworks Inc. Methods of quantitating heavy and light chain polypeptide pairs
UY35148A (en) 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
MX385344B (en) 2012-11-28 2025-03-18 Zymeworks Bc Inc GENETICALLY MODIFIED IMMUNOGLOBULIN HEAVY CHAIN-LIGHT CHAIN PAIRS AND THEIR USES.
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
HK1218930A1 (en) 2013-02-08 2017-03-17 Abbvie Stemcentrx Llc Novel multispecific constructs
ES2821753T3 (en) 2013-03-15 2021-04-27 Lilly Co Eli Fab and bispecific antibody production procedures
CA2910945A1 (en) 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
AU2014287011A1 (en) 2013-07-12 2016-02-25 Zymeworks Inc. Bispecific CD3 and CD19 antigen binding constructs
EP3143043B1 (en) 2014-05-16 2022-12-14 Pfizer Inc. Bispecific antibodies with engineered ch1-cl interfaces
HK1231490A1 (en) * 2014-05-28 2017-12-22 Zymeworks, Inc. Modified antigen binding polypeptide constructs and uses thereof
GB201414823D0 (en) 2014-08-20 2014-10-01 Argen X Bv Multispecific antibodies
JP6952605B2 (en) 2015-04-24 2021-10-20 ジェネンテック， インコーポレイテッド Multispecific antigen binding protein
EP4524161A3 (en) 2015-10-08 2025-06-04 Zymeworks BC Inc. Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12060436B2 (en) 2012-11-28 2024-08-13 Zymeworks Bc Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof

Also Published As

Publication number Publication date
WO2015181805A1 (en) 2015-12-03
US20250215115A1 (en) 2025-07-03
MX2016015459A (en) 2017-12-14
US20220251242A1 (en) 2022-08-11
US12286489B2 (en) 2025-04-29
EP3107938A1 (en) 2016-12-28
WO2015181805A9 (en) 2016-02-25
RU2016145906A3 (en) 2018-05-23
RU2016145906A (en) 2018-05-23
RU2729467C2 (en) 2020-08-06
CA2946503A1 (en) 2015-12-03
MX2022006527A (en) 2022-07-11
EP3107938A4 (en) 2018-02-28
AU2015265457A1 (en) 2016-11-10
EA201692476A1 (en) 2017-07-31
US20170204199A1 (en) 2017-07-20
AU2024202649A1 (en) 2024-05-16
EP3107938B1 (en) 2022-05-04
MX392772B (en) 2025-03-24
CA3177027A1 (en) 2015-12-03
CA3177027C (en) 2025-05-06
US11306156B2 (en) 2022-04-19
KR20170044613A (en) 2017-04-25
AU2021202963A1 (en) 2021-06-03
CA3244731A1 (en) 2025-11-29
CA2946503C (en) 2022-11-22
EP4026850A1 (en) 2022-07-13
DK3107938T3 (en) 2022-07-11
BR112016027888A2 (en) 2017-10-24
KR102493430B1 (en) 2023-01-31
AU2021202963B2 (en) 2024-02-15
AU2015265457B2 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
HK1231490A1 (en) Modified antigen binding polypeptide constructs and uses thereof
MX2021000156A (en) Engineered immunoglobulin heavy chain-light chain pairs and uses thereof.
EP4524161A3 (en) Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
EP4491195A3 (en) Bispecific tetravalent antibodies and methods of makiing and using thereof
ZA202211577B (en) Multivalent and multispecific 41bb-binding fusion proteins
IL280673A (en) Proteins that bind nkg2d, cd16, and tumor-associated antigen
IL281305A (en) Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1
IL268755A (en) HER2, NKG2D, and CD16 binding proteins
WO2015106080A3 (en) Antibodies directed against interleukin-33 (il-33)
CY1123615T1 (en) POLYSTENA AND MULTISPECIES FUSION PROTEINS THAT BIND DR5
MX2024004017A (en) Multivalent and multispecific ox40-binding fusion proteins.
MX2020006896A (en) Anti-tigit antibodies and their use as therapeutics and diagnostics.
NZ725568A (en) Modified j-chain
WO2014182676A3 (en) Compositions and methods for growth factor modulation
IL280618A (en) Proteins that bind NKG2D, CD16 and tumor-associated antigen
WO2016073879A3 (en) Transforming growth factor-related antibodies and uses thereof
EA201891709A1 (en) ANTIGENSBINKING PROTEINS, BINDING PD-L1
CL2017001070A1 (en) Variants of interferon a2b
WO2014012085A3 (en) Bispecific asymmetric heterodimers comprising anti-cd3 constructs
EA201491599A1 (en) ANTIBODIES TO MATRIX METALLOPROTEINASE 9
MX387180B (en) FC REGION VARIANTS WITH NEONATAL FC RECEPTOR (FCRN) BINDING PROPERTIES.
MY172718A (en) Humanized universal light chain mice
PH12021550289A1 (en) Ox40-binding polypeptides and uses thereof
EA201892063A1 (en) MODIFIED IMMUNE GLOBULINS WITH MODIFIED FcRn BINDING
MX2023006786A (en) Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors.

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: CORRECTION OF NAME OF INVENTOR FROM DIXIT, SURGIT BHIMARAO TO DIXIT

Effective date: 20180615